# Bob More

> Bob More is a Series A investor at Alta Partners (Seattle) backing Biotechnology and Life Science. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Alta Partners](https://shizune.co/investors/profile/alta-partners)
- Location: Seattle, United States
- Total investments: 3
- Last investment: Nov 2023
- Lead investor: 67%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/pub/bob-more/42/950/ab3 
- X (Twitter): https://twitter.com/Bobmorevc
- Website: https://x.com/Bobmorevc

Bob More is a Series A investor at Alta Partners in Seattle focused on Biotechnology and Life Science. Bob More is based out of Cambridge, Massachusetts, and is the Board Director of EGenesis. Bob previously worked at Biotechnology Innovation Organization as Board. Bob More attended Middlebury College.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 67% |
| Life Science | 1 | 33% |
| Therapeutics | 1 | 33% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 67% |
| Series B | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| MBrace Therapeutics | MBrace Therapeutics is a privately held biopharmaceutical business dedicated to improving cancer patients' quality of life by developing antibody-drug conjugates (ADCs) against novel oncology targets. | $85M | Series B | Nov 14, 2023 |  |
| MBrace Therapeutics | MBrace Therapeutics is a privately held biopharmaceutical business dedicated to improving cancer patients' quality of life by developing antibody-drug conjugates (ADCs) against novel oncology targets. | $25M | Series A | Jan 01, 2021 |  |
| Tyra Biosciences | Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. Tyra is using its proprietary SNÅP platform, which is optimized to enable rapid and precise refinement of structural design through iterative molecular SNÅPshots, in orderto generate next-generation product candidates that are specifically designed to address acquired drug resistance and provide alternative treatment options. Tyra is initially focused on developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor, or FGFR, family, which are altered in approximately 7% of all cancers. Tyra’s lead product candidate, TYRA-300, is designed to selectively inhibit FGFR3, with an initial focus on patients with bladder cancer. | $50M | Series A | Jan 10, 2020 |  |

3 of 3 investments shown.

## Co-investors
- [Venrock](https://shizune.co/investors/profile/venrock) — VC Fund, 3 deals together
- [Avidity Partners](https://shizune.co/investors/profile/avidity-partners) — VC Fund, 1 deal together
- [Boxer Capital](https://shizune.co/investors/profile/boxer-capital) — VC Fund, 1 deal together
- [Canaan Partners](https://shizune.co/investors/profile/canaan-partners) — VC Fund, 1 deal together
- [Cowen Healthcare Investments](https://shizune.co/investors/profile/cowen-healthcare-investments) — VC Fund, 1 deal together
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 1 deal together

## About Alta Partners

VC Fund · San Francisco, United States

Alta Partners is a venture capital firm investing in the healthcare and life sciences sector. Their diverse and integrated team brings together a powerful depth of knowledge and experience, delivering tangible results for their companies and their investors.

5 contacts available at Alta Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Dan Janney | Managing Director | https://shizune.co/investors/profile/dan-janney |
| Peter Hudson | Managing Director | https://shizune.co/investors/profile/peter-hudson-2 |
| Alison de Bord | Director | https://shizune.co/investors/profile/alison-de-bord |
| Bob More | Managing Director | https://shizune.co/investors/profile/bob-more |
| Edward Penhoet | Director | https://shizune.co/investors/profile/ed-penhoet |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Bob More invest in?

Bob More invests primarily in Biotechnology, Life Science and Therapeutics startups, most often at Series A and Series B stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Bob More last invest?

The most recent investment recorded for Bob More closed in Nov 2023. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co